

Name	**Chapuy, Björn, Univ.-Prof. Dr. med.** *12.06.1977, German
Address	University Medical Center Göttingen (UMG) Department of Hematology and Oncology Robert-Koch Str. 40 37075, Göttingen, Germany Phone: +49-551-39-7075 Fax: +49-551-39-8587 Email: bjoern.chapuy@med.uni-goettingen.de
Family Status	Married, two kids
Position	Professor (W2 tenure track), physician

Academic education

1997-2004	Medical School, UMG, Germany

Scientific degrees

2012	Junior Faculty/Instructor in Medicine, Dana-Farber Cancer Institute/Harvard Medical School (DFCI/HWS), Boston, MA, USA
2006	MD thesis, Department of Biochemistry/Cell Biology (Prof. Dr. von Figura/ Prof. Dr. S. Höning), UMG (*Summa cum laude*)
2004	Unlimited License to practice medicine in Germany
2004	Graduation from Medical School, UMG, Göttingen

Scientific career

11/2019-today	Steering board member, German Lymphoma Alliance (GLA)
10/2018-today	Contact person for aggressive B-cell lymphoma, DNA sequencing and epigenetics in the Correlative Science Work Group of the GLA
2019-today	Member of the Research Council (Forschungskommission), UMG
2019-today	Member of the Mice Facility Control Council, UMG
02/2018-today	Professor of Tumor Biology and Signal Transduction (W2tt), UMG, Germany
12/2017-today	Coordination team, Else Kröner-Fresenius MD Program (Promotionskolleg), UMG
2009-today	Affiliated Member, Broad Institute, Cambridge, MA, USA
2016-2017	Declined Assistant Professor positions at Harvard Medical School (Boston, MA, USA) and MD Anderson Cancer Center (Houston, TX, USA) and Associate Professor (W2-Ruf) at Charité, Berlin, Germany
2012 - 2018	Junior Faculty/Instructor in Medicine, Lymphoma Program, DFCI/HMS, Boston, MA, USA
2008 - 2012	Postdoctoral fellow with Prof. Dr. M. Shipp, Lymphoma Program, DFCI/HWS, Boston, MA, USA
2004 - 2008	Research Associate with Prof. Dr. G. Wulf, Department of Hematology and Oncology, UMG
2004 - 2008	Combined residency and clinical fellowship in Hematology and Oncology, Department of Hematology and Oncology, UMG

Honors / Awards

2018	Oncology Award, Gilead Science GmbH
2018 -	Grant reviewer for German Cancer Aid, Foundation of Polish Science, Swiss Cancer League
2014 -	Adhoc reviewer for *Cancer Discovery, Nature Communications, Blood, Leukemia, EMBO J, Blood Advances, Clinical Cancer Research, Cancer Research, Hematologica, etc.*
2016	Medical Oncology Translational Grant Award, DFCI/HWS
2014	Claudia Adams Barr Award for Basic Cancer Research
2012 - 2015	American Society of Hematology Achievement Award (each year)
2008 - 2010	Research fellowship, DFG
2006	Young investigator award, UMG

Memberships

1) Deutsche Gesellschaft für Innere Medizin
2) Deutsche Gesellschaft für Hämatologie und Onkologie
3) Deutscher Hochschulverband
4) German Lymphoma Alliance
5) American Society of Hematology
6) American Association for Cancer Research

Patents

Inventors	Bradner, J.E., McKeown, M.R., Shipp, M.A., **Chapuy, B.**, Wong, K.K., Chen, Z.
Application #	US Patent Application Serial No. 61/901,90 filed November 8, 2013
Title	Combination therapy for cancer using bromodomain and extra-terminal (BET) Protein inhibitors
Abstract	We patented the use of BET-inhibitors and rational combination partners in cancer including diffuse large B-cell lymphomas and related disorders.

Inventors	Rodig J, Carey CD, Shipp MA, Monti S, Gusenleitner D, **Chapuy B**
Application #	World Patent Application: 2015/157291. Filed July 4, 2015.
Title	Classification of MYC-driven B-cell
Abstract	This application protects a nanostring-based approach to classify B-cell lymphomas depending on their MYC expression.

Inventors	**Chapuy B**, Shipp MA, Chip S, Dunfort A, Getz G
Application #	US Patent Application Serial No. 62/646,214 filed March 21, 2018
Title	Therapeutic Treatment of Select Diffuse Large B Cell Lymphomas Exhibiting Distinct Pathogenic Mechanisms and Outcomes
Abstract	This application protects the classifier and associated kits as well as subset-specific treatment associated to the genetic classification of DLBCLs.

10 most important publications (* denotes equal contributions)

1. **Chapuy B***, Stewart C*, Dunford AJ*, Kim J, Wienand K, Kamburov A, Griffin GK, Chen PH, Lako A, Redd R, Cote CM, Ducar MD, Thorner AR, Rodig SJ, Getz G, Shipp MA. Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade. ***Blood***. 2019 Dec 26;134(26):2369-2382. doi: 10.1182/blood.2019002067.
2. **Chapuy B***, Stewart C*, Dunford A* (* denotes equal contribution), Kim J, Kamburov A, Redd R, Lawrence M, Roemer MGM, Li AJ, Ziepert M, Wala J, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin C, Hess J, Pedamallu C, Livitz D, Rosenbrock D, Rosenberg M, Tracy A, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson M, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg D, Loeffler M, Pfreundschuh M, Trümper L, Getz G*, Shipp MA*. Molecular Subtypes of Diffuse Large B-cell Lymphoma are Associated with Distinct Pathogenic Mechanisms and Outcomes. ***Nat Med.*** 2018 May;24(5):679-690.
3. **Chapuy B***, Roemer MGM*(*=equal contributions), Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden E, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon K, Ferry, JA, Freeman G, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA: Targetable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. ***Blood.*** 2016 Feb 18;127(7):869-81.
4. **Chapuy B***,Cheng H* (*=equal contributions), Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MGM, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, Weinstock DM, Monti S, Rodig SJ, Wang Y, Shipp MA. Diffuse Large B-cell Lymphoma Patient-derived Xenograft Models Capture the Molecular and Biologic Heterogeneity of the Disease. ***Blood.*** 2016 May 5;127(18):2203-13.
5. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, **Chapuy B**, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. ***NEJM.*** 2015 Jan 22;372(4):311-9.

6. Karreth FA, Reschke M, Ruocco A, Ng C, **Chapuy B**, LéopoldV, Sjoberg M, Keane TM, Verma A, Ala U, Tay Y, Seitzer N, Bothmer A, Fung J, Langellotto F, Rodig SJ, Elemento O, Shipp MA, Adams DJ, Chiarle R, Pandolfi PP: The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. ***Cell.*** 2015 Apr 9;161(2):319-32.
7. Lane AA, **Chapuy B**, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu S, Liu H, Yoda A, Alexe G, Schinze AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris M, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM: Chr.21q22 triplication contributes to B cell transformation through HMGN1 and loss of H3K27me3. ***Nat Genet.*** 2014 Jun;46(6):618-23.
8. **Chapuy B***, McKeown MR* (*=equal contributions), Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun H, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE: Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma. ***Cancer Cell.*** 2013 Dec 9;24(6):777-90.
9. Monti S*, **Chapuy B*** (*=equal contributions), Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Curie T, Dogan A, Kutok JL, Beroukim R, Neuberg D, Habermann T, Getz G, Kung AL, Golub TR, Shipp MA: Integrative Analysis Reveals an Outcome-associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B-cell Lymphoma. ***Cancer Cell.*** 2012 Sep 11;22(3):359-72.
10. Duan S*, Cermak L* , (*=equal contributions), Pagan J, Rossi M, Francia di Celle P, **Chapuy B**, Shipp B, Chiarle R, Pagano M: The F-box protein FBXO11 targets BCL6 for degradation and is mutated in Diffuse Large B-Cell Lymphomas, leading to BCL6 stabilization. ***Nature.*** 2012 Jan 5;481(7379):90-3.